BACKGROUND/AIM: Immunotherapy with checkpoint inhibitors is currently considered a cornerstone of metastatic renal clear cell cancer (mRCC) therapy. Despite the general improvement in the survival of patients with mRCC, there are some clinical situations that have not been specifically evaluated in clinical trials, such as the use of everolimus before nivolumab. PATIENTS AND METHODS: We performed a retrospective analysis evaluating the efficacy of nivolumab in the real-world setting, including a subset of patients with previous mTOR inhibitor therapy. RESULTS: From a total of 56 patients, 25 were pre-treated with everolimus before receiving nivolumab. The overall progression-free survival (PFS), overall survival (OS), and objective response rate were 10.3, 21.3 months, and 34%, respectively. There were no statistically significant differences in patients who were or were not pre-treated with everolimus. CONCLUSION: mRCC patients should be treated with checkpoint inhibitors and prior use of mTOR inhibitors should not be a definitive exclusion criterium.

Department of Comprehensive Cancer Care Faculty of Medicine Masaryk University Brno Czech Republic

Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Brno Czech Republic

Department of Oncology 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Department of Oncology 1st Faculty of Medicine Charles University and Thomayer Hospital Prague Czech Republic

Department of Oncology and Radiotherapy Faculty of Medicine and University Hospital Hradec Kralove Hradec Kralove Czech Republic

Department of Oncology and Radiotherapy Faculty of Medicine and University Hospital Hradec Kralove Hradec Kralove Czech Republic;

Department of Oncology Palacky University Medical School and Teaching Hospital Olomouc Czech Republic

Department of Oncology St Anne's University Hospital Brno Brno Czech Republic

Department of Oncology University Hospital Ostrava Ostrava Czech Republic

Zobrazit více v PubMed

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P, CheckMate 025 Investigators Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–1813. doi: 10.1056/NEJMoa1510665. PubMed DOI PMC

Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, Rha SY, Agarwal N, Kollmannsberger C, Rini BI, Choueiri TK. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141–148. doi: 10.1016/S1470-2045(12)70559-4. PubMed DOI PMC

Teishima J, Inoue S, Hayashi T, Mita K, Hasegawa Y, Kato M, Kajiwara M, Shigeta M, Maruyama S, Moriyama H, Fujiwara S, Matsubara A. Impact of the systemic immune-inflammation index for the prediction of prognosis and modification of the risk model in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors. Can Urol Assoc J. 2020;14(11):E582–E587. doi: 10.5489/cuaj.6413. PubMed DOI PMC

Zhong JH, Huang DH, Chen ZY. Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8(43):75381–75388. doi: 10.18632/oncotarget.18856. PubMed DOI PMC

Hu K, Lou L, Ye J, Zhang S. Prognostic role of the neutrophil-lymphocyte ratio in renal cell carcinoma: a meta-analysis. BMJ Open. 2015;5(4):e006404. doi: 10.1136/bmjopen-2014-006404. PubMed DOI PMC

Wang Z, Peng S, Wang A, Xie H, Guo L, Jiang N, Niu Y. Platelet-lymphocyte ratio acts as an independent predictor of prognosis in patients with renal cell carcinoma. Clin Chim Acta. 2018;480:166–172. doi: 10.1016/j.cca.2018.02.014. PubMed DOI

Kopecký J, Kubeček O, Geryk T, Slováčková B, Hoffmann P, Žiaran M, Priester P. Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report. J Med Case Rep. 2018;12(1):262. doi: 10.1186/s13256-018-1786-9. PubMed DOI PMC

Albiges L, Negrier S, Dalban C, Chevreau C, Gravis G, Oudard S, Laguerre B, Barthelemy P, Borchiellini D, Gross-Goupil M, Geoffrois L, Rolland F, Thiery-Vuillemin A, Joly F, Ladoire S, Tantot F, Escudier B, GETUG Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mrcc): Final analysis from the nivoren getug afu 26 study. J Clin Oncol. 2019;37:542–542. doi: 10.1200/JCO.2019.37.7_suppl.542. PubMed DOI

Albiges L, Negrier S, Dalban C, Gravis G, Chevreau C, Oudard S, Laguerre B, Barthelemy P, Borchiellini D, Gross-Goupil M, Geoffrois L, Brihoum M, Escudier B, GETUG Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mrcc): Results from the nivoren getug-afu 26 study. J Clin Oncol. 2018;36:577–577. doi: 10.1200/JCO.2018.36.6_suppl.577. DOI

De Giorgi U, Cartenì G, Giannarelli D, Basso U, Galli L, Cortesi E, Caserta C, Pignata S, Sabbatini R, Bearz A, Buti S, Lo Re G, Berruti A, Bracarda S, Cognetti F, Rastelli F, Fornarini G, Porta C, Turci D, Sternberg CN, Procopio G, Italian Nivolumab Renal Cell Cancer Early Access Program Group Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. BJU Int. 2019;123(1):98–105. doi: 10.1111/bju.14461. PubMed DOI

Grimm M-O, Grünwald V, Heyde E, Herber M, Mueller-Huesmann H, Bedke J. Real world data on the use of nivolumab and ipilimumab combination therapy or nivolumab monotherapy in the treatment of renal cell carcinoma: Interim results from the non-interventional study (NIS) NORA. European Urology Open Science. 2020;19:e1107. doi: 10.1016/S2666-1683(20)33323-1. DOI

Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931–1939. doi: 10.1016/S0140-6736(11)61613-9. PubMed DOI

Huang HF, Fan XR, Ji ZG. The effectiveness of sorafenib over other targeted agents in the second-line treatment of metastatic renal cell carcinoma: a meta-analysis. Pathol Oncol Res. 2019;25(4):1497–1503. doi: 10.1007/s12253-018-0516-3. PubMed DOI

Koutsoukos K, Bamias A, Tzannis K, Espinosa Montaño M, Bozionelou V, Christodoulou C, Stefanou D, Kalofonos H, Duran I, Papazisis K. Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib. Onco Targets Ther. 2017;10:4885–4893. doi: 10.2147/OTT.S141260. PubMed DOI PMC

Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DYC, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ, METEOR investigators Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917–927. doi: 10.1016/S1470-2045(16)30107-3. PubMed DOI

Motzer RJ, Hutson TE, Ren M, Dutcus C, Larkin J. Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. Lancet Oncol. 2016;17(1):e4–e5. doi: 10.1016/S1470-2045(15)00543-4. PubMed DOI

Huijts CM, Santegoets SJ, de Jong TD, Verheul HM, de Gruijl TD, van der Vliet HJ. Immunological effects of everolimus in patients with metastatic renal cell cancer. Int J Immunopathol Pharmacol. 2017;30(4):341–352. doi: 10.1177/0394632017734459. PubMed DOI PMC

Hirayama Y, Gi M, Yamano S, Tachibana H, Okuno T, Tamada S, Nakatani T, Wanibuchi H. Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma. Cancer Sci. 2016;107(12):1736–1744. doi: 10.1111/cas.13099. PubMed DOI PMC

Zhang Q, Liu H, Wang H, Lu M, Miao Y, Ding J, Li H, Gao X, Sun S, Zheng J. Lenvatinib promotes antitumor immunity by enhancing the tumor infiltration and activation of NK cells. Am J Cancer Res. 2019;9(7):1382–1395. PubMed PMC

Boissier R, Campagna J, Branger N, Karsenty G, Lechevallier E. The prognostic value of the neutrophil-lymphocyte ratio in renal oncology: A review. Urol Oncol. 2017;35(4):135–141. doi: 10.1016/j.urolonc.2017.01.016. PubMed DOI

Dalpiaz O, Luef T, Seles M, Stotz M, Stojakovic T, Pummer K, Zigeuner R, Hutterer GC, Pichler M. Critical evaluation of the potential prognostic value of the pretreatment-derived neutrophil-lymphocyte ratio under consideration of C-reactive protein levels in clear cell renal cell carcinoma. Br J Cancer. 2017;116(1):85–90. doi: 10.1038/bjc.2016.393. PubMed DOI PMC

Wang X, Su S, Guo Y. The clinical use of the platelet to lymphocyte ratio and lymphocyte to monocyte ratio as prognostic factors in renal cell carcinoma: a systematic review and meta-analysis. Oncotarget. 2017;8(48):84506–84514. doi: 10.18632/oncotarget.21108. PubMed DOI PMC

Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009;10(10):992–1000. doi: 10.1016/S1470-2045(09)70240-2. PubMed DOI

Heng DY, Mackenzie MJ, Vaishampayan UN, Bjarnason GA, Knox JJ, Tan MH, Wood L, Wang Y, Kollmannsberger C, North S, Donskov F, Rini BI, Choueiri TK. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Ann Oncol. 2012;23(6):1549–1555. doi: 10.1093/annonc/mdr533. PubMed DOI PMC

Busch J, Seidel C, Weikert S, Wolff I, Kempkensteffen C, Weinkauf L, Hinz S, Magheli A, Miller K, Grünwald V. Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma. BMC Cancer. 2011;11:295. doi: 10.1186/1471-2407-11-295. PubMed DOI PMC

Bersanelli M, Iacovelli R, Buti S, Houede N, Laguerre B, Procopio G, Lheureux S, Fischer R, Negrier S, Ravaud A, Oudard S, Escudier B, Albiges L, Porta C. Metastatic renal cell carcinoma rapidly progressive to sunitinib: What to do next. Eur Urol Oncol. 2021;4(2):274–281. doi: 10.1016/j.euo.2019.06.018. PubMed DOI

Sambi M, Bagheri L, Szewczuk MR. Current challenges in cancer immunotherapy: Multimodal approaches to improve efficacy and patient response rates. J Oncol. 2019;2019:4508794. doi: 10.1155/2019/4508794. PubMed DOI PMC

Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma